Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty.
OBJECTIVE
To report the effect of long-term treatment with the tyrosine kinase inhibitor imatinib started before the onset of puberty on semen parameters, bone mineral density, and hormone values.


METHODS
Case report.


METHODS
University hospital.


METHODS
An 18-year-old man given treatment with imatinib for chronic myeloid leukemia.


METHODS
Clinical, biochemical and dual-energy X-ray absorptiometry evaluations.


METHODS
Semen analysis, serum levels of gonadotropins, inhibin-B, and testosterone, bone mineral density, markers of skeletal homeostasis.


RESULTS
Semen analyses showed severe oligozoospermia after long-term administration of imatinib started before puberty. The inhibin-B/FSH ratio was reduced. A low bone mineral density for chronologic age was observed.


CONCLUSIONS
This case study documents the potential risk of an impairment of semen parameters in patients undergoing a treatment with tyrosine kinase inhibitors before the complete maturation of the testis.
Mariani
Stefania
S
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Basciani
Sabrina
S
Fabbri
Andrea
A
Agati
Luciano
L
Ulisse
Salvatore
S
Lubrano
Carla
C
Spera
Giovanni
G
Gnessi
Lucio
L
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy*; D008297:Male; D009845:Oligospermia / Q000139:chemically induced*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011627:Puberty; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate